Table 2.

Reported incidence rates and values of each treatment-related grade ⩾3 adverse events.

Adverse event	Reported incidence rate (%)		Cost and disutility values
	Nivolumab-combination	Gemcitabine–cisplatin	Cost in January 2024 USD (2015 USD)	Disutility
Anemia	22	17.7	8796.53 (6944.06)	0.073
Neutropenia	22	17.7	15,512.63 (12,245.81)	0.2
Decreased neutrophil count	22	17.7	15,546.49 (12,272.54)	0.2
Decreased platelet count	18.8	15.3	8277.05 (6533.98)	0.2
Decreased white-cell count	18.8	15.3	12,986.55 (10,251.70)	0.19
Thrombocytopenia	18.8	15.3	12,986.55 (10,251.70)	0.19